Gentamicin Two-Level Elimination Rate Constant: Clinical Pharmacology Guide

Overview

Calculates the first-order elimination rate constant for Gentamicin from two post-distribution serum concentrations and their sampling times.

Clinical Significance

The result describes the apparent post-distribution elimination slope of Gentamicin. It should be used only with correctly timed levels and a compatible one-compartment model.

When to Use

• Use when the required concentration, timing and dosing information are reliable and the stated pharmacokinetic assumptions are reasonable.
• Use within an approved therapeutic-drug-monitoring or medicines-governance pathway.
• Use to support transparent review, not to automate prescribing.

How It Is Calculated

• k = ln(C1 ÷ C2) ÷ (t2 − t1).
• MedicalC validates that all required inputs are numeric and rejects internally impossible time or concentration relationships where applicable.

Interpretation

• The result describes the apparent post-distribution elimination slope of Gentamicin. It should be used only with correctly timed levels and a compatible one-compartment model.
• Interpret the result with the clinical indication, microbiology or seizure control, organ function, assay timing and local targets.

Worked Example

Enter a verified set of source values in the displayed units. MedicalC applies: k = ln(C1 ÷ C2) ÷ (t2 − t1). Recheck the source chart and sampling times before using the result.

Patient Considerations

• Primarily intended for clinically stable adults receiving intermittent intravenous aminoglycoside therapy. Paediatric, neonatal, pregnancy, obesity, burns, cystic fibrosis, dialysis and rapidly changing renal function require specialist protocols.
• Consider acute kidney injury, augmented renal clearance, fluid shifts, obesity, burns, pregnancy, critical illness and interacting medicines.

Limitations

• One-compartment equations may not describe distribution or multicompartment behaviour accurately.
• Derived values can appear precise despite uncertainty in sampling time, assay result and clearance stability.
• A calculated exposure or dose does not establish clinical benefit or safety.

Clinical Pearls

• A negative or near-zero slope usually signals reversed times, mistimed samples, assay noise, ongoing distribution or an undocumented dose.
• Plot concentrations against actual elapsed time before accepting any pharmacokinetic slope.
• When the result conflicts with the patient, verify the data rather than forcing a dose change.

Common Mistakes

• Using scheduled rather than actual administration and blood-sampling times.
• Treating a level drawn during distribution as a post-distribution concentration.
• Mixing mg/L, micrograms/mL and micrograms/L.
• Applying steady-state equations before steady state or during changing clearance.
• Using a generic concentration target outside the relevant indication or local protocol.

Evidence Base

Principal source: Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. McGraw-Hill; 2015.

References

1. Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. McGraw-Hill; 2015. — Primary publication, consensus guideline or authoritative pharmacokinetic source.